Needham analyst Joseph Stringer downgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Buy to Hold.

For an analyst ratings summary and ratings history on Apellis Pharmaceuticals click here. For more ratings news on Apellis Pharmaceuticals click here.

Shares of Apellis Pharmaceuticals closed at $17.09 yesterday.